• No results found

MeDeCom: discovery and quantification of latent components of heterogeneous methylomes

N/A
N/A
Protected

Academic year: 2020

Share "MeDeCom: discovery and quantification of latent components of heterogeneous methylomes"

Copied!
20
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Fig. 1 Computational framework of MeDeCom. a The conceptional background of MeDeCom. The measured methylomes (e.g., as 450K data, shown
Fig. 2 is shown) for MeDeCom and RefFreeCellMix. RefFreeCellMix misinterprets the most extreme mixtures as pure cell types T (see Fig
Table 1 Public Infinium 450k data sets used in the study
Fig. 3 Results for blood cell methylomes.CpGs differentially methylated between LMC2 and LMC13 from the PureBC data set
+2

References

Related documents

Findings reveal that culture, politics, dependence and trust have a significant influence on relationship quality in supply chain collaborations amongst purchasers and

de promethazimia-ha essite usate extensemente como tranquilhisatores in patientes pediatric, usualmente in he tractamento symptomatic de miausea e vomito. Es reportate 9

Discussion: This article is a study into the case of the Danish Circumcision Registry. We show that such a registry may lead to various forms of harm such as 1) overreaching

For example, some participants re- ported that they anticipated it would remove risks associated with patients losing and forgetting paper notes, improve clinical audits and

A complete type of annular pancreas with duodenal stenosis was found, and dilated common bile duct with high confluence of pancreaticobiliary ducts was also observed..

The aim of the study was to assess the presence of pathogenic microbes on treatment tables in one outpatient teaching clinic and determine a simple behavioral model for

This paper has undertaken a systematic review of global and local (Pakistan) information from conflict areas on platforms of health service provision in the last 10 years

The results were sensitive to: the remission rates maintained in responders to 'usual care' and to 5 mg/kg infliximab, the rate of remission induced by adalimumab in non-responders to